01988nas a2200409   4500000000100000000000100001008004100002260001500043653003100058653001500089100001300104700001900117700001900136700001400155700001900169700001700188700001900205700002000224700002000244700002000264700001700284700002200301700002200323700001800345700002200363700002000385700002300405700001500428700001700443700001900460245007000479856005500549300000800604490000600612520094600618022001401564       2022                            d  c2022-05-3010aRespiratory Tract Diseases10aSARS-CoV-21 aEmi Sano1 aTatsuya Suzuki1 aRina Hashimoto1 aYumi Itoh1 aAyaka Sakamoto1 aYusuke Sakai1 aAkatsuki Saito1 aDaisuke Okuzaki1 aDaisuke Motooka1 aYukiko Muramoto1 aTakeshi Noda1 aTomohiko Takasaki1 aJun-Ichi Sakuragi1 aShohei Minami1 aTakeshi Kobayashi1 aTakuya Yamamoto1 aYasufumi Matsumura1 aMiki Nagao1 aToru Okamoto1 aKazuo Takayama00aCell response analysis in SARS-CoV-2 infected bronchial organoids  uhttps://www.nature.com/articles/s42003-022-03499-2  a1-90 v53 aThe development of an in vitro cell model that can be used to study severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) research is expected. Here we conducted infection experiments in bronchial organoids (BO) and an BO-derived air-liquid interface model (BO-ALI) using 8 SARS-CoV-2 variants. The infection efficiency in BO-ALI was more than 1,000 times higher than that in BO. Among the bronchial epithelial cells, we found that ciliated cells were infected with the virus, but basal cells were not. Ciliated cells died 7 days after the viral infection, but basal cells survived after the viral infection and differentiated into ciliated cells. Fibroblast growth factor 10 signaling was essential for this differentiation. These results indicate that BO and BO-ALI may be used not only to evaluate the cell response to SARS-CoV-2 and coronavirus disease 2019 (COVID-19) therapeutic agents, but also for airway regeneration studies.  a2399-3642